Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Acquired Resistance to Erlotinib in EGFR Mutation-Positive Lung Adenocarcinoma among Hispanics (CLICaP).

Targeted oncology - 1 Aug 2017

Cardona Andrés F, Arrieta Oscar, Zapata Martín Ignacio, Rojas Leonardo, Wills Beatriz, Reguart Noemí, Karachaliou Niki, Carranza Hernán, Vargas Carlos, Otero Jorge, Archila Pilar, Martín Claudio, Corrales Luis, Cuello Mauricio, Ortiz Carlos, Pino Luis E, Rosell Rafael, Zatarain-Barrón Zyanya Lucia

Abstract excerpt

BACKGROUND: Lung cancer harboring epidermal growth factor receptor (EGFR) mutations and treated with EGFR tyrosine kinase inhibitors (TKIs) all eventually develop acquired resistance to the treatment, with half of the patients developing EGFR T790M resistance mutations. OBJECTIVE: The purpose of this study was to assess histological and clinical characteristics and survival outcomes in Hispanic EGFR mutated lung...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Adenocarcinoma
Share to Adenocarcinoma of Lung

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Antineoplastic Agents

Share to Disease Progression

Share to Drug Resistance, Neoplasm

Share to ErbB Receptors

Share to Erlotinib Hydrochloride

Share to Hispanic or Latino

Source

Identifiers

PMID: 28620690
DOI: 10.1007/s11523-017-0497-2

Genes

EGFR
KRAS
MET

Variants

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 3 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Acquired Resistance to Erlotinib in EGFR Mutation-Positive Lung Adenocarcinoma among Hispanics (CLICaP).PMID 28620690Read ↗

Mechanisms of Resistance to First-Line Osimertinib in Hispanic Patients With EGFR Mutant Non-Small Cell Lung Cancer (FRESTON-CLICaP).Semantic proximity Read ↗

Oncogenic drivers in nonsmall cell lung cancer and resistance to epidermal growth factor receptor tyrosine kinase inhibitors.Semantic proximity Read ↗

Lung cancer mutations and use of targeted agents in Hispanics.Semantic proximity Read ↗

Analysis of tumor specimens at the time of acquired resistance to EGFR-TKI therapy in 155 patients with EGFR-mutant lung cancers.Semantic proximity Read ↗

Acquired resistance to EGFR tyrosine kinase inhibitors in EGFR-mutant lung cancer: distinct natural history of patients with tumors harboring the T790M mutation.Semantic proximity Read ↗

Treatment of EGFR-Mutant Lung Cancers After Progression in Patients Receiving First-Line EGFR Tyrosine Kinase Inhibitors : A Review.Semantic proximity Read ↗

EGFR: The Paradigm of an Oncogene-Driven Lung Cancer.Semantic proximity Read ↗

Activating and resistance mutations of the epidermal growth factor receptor (EGFR) gene and non-small cell lung cancer: a clinical reality.Semantic proximity Read ↗

Acquired EGFR T790M Mutation After Relapse Following EGFR-TKI Therapy: A Population-based Multi-institutional Study.Semantic proximity Read ↗

Genomic Landscape of Primary Resistance to Osimertinib Among Hispanic Patients with EGFR-Mutant Non-Small Cell Lung Cancer (NSCLC): Results of an Observational Longitudinal Cohort Study.Semantic proximity Read ↗

Heterogeneity in resistance mechanisms causes shorter duration of epidermal growth factor receptor kinase inhibitor treatment in lung cancer.Semantic proximity Read ↗

Attacking a Moving Target: Understanding Resistance and Managing Progression in EGFR-Positive Lung Cancer Patients Treated With Tyrosine Kinase Inhibitors.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.